Bradykinin antagonists as anti-cancer agents

Related Experiment Video

Updated: Aug 30, 2026

Assessment of Resistance to Tyrosine Kinase Inhibitors by an Interrogation of Signal Transduction Pathways by Antibody Arrays
07:42

Assessment of Resistance to Tyrosine Kinase Inhibitors by an Interrogation of Signal Transduction Pathways by Antibody Arrays

Published on: September 19, 2018

J M Stewart1

  • 1Department of Biochemistry and Molecular Genetics University of Colorado School of Medicine 4200 E. Ninth Ave. Denver, CO 80262 USA. john.stewart@uchsc.edu

Current Pharmaceutical Design
|October 8, 2003
PubMed

Insights

Bradykinin antagonists show significant anti-cancer effects by promoting cancer cell death and inhibiting tumor growth. These novel compounds demonstrate potent efficacy and low toxicity, offering promising new therapeutic strategies for lung and prostate cancers.

Area of Science:

  • Oncology
  • Pharmacology
  • Molecular Biology

Background:

  • Bradykinin acts as a key growth factor in various cancers, particularly lung and prostate.
  • Existing bradykinin antagonists have demonstrated anti-cancer properties in preclinical models.

Purpose of the Study:

  • To investigate the anti-cancer mechanisms and efficacy of novel bradykinin antagonists.
  • To evaluate the therapeutic potential of these antagonists in lung and prostate cancer models.

Main Methods:

  • Utilized in vitro and in vivo cancer models, including nude mouse xenotransplants.
  • Analyzed apoptosis induction via biased agonism, affecting calcium and MAP kinase pathways.
  • Assessed inhibition of angiogenesis and matrix metalloproteinases (MMP-2 and MMP-9).

Main Results:

  • Bradykinin antagonists induced apoptosis through a biased agonist mechanism, activating caspases.
  • Inhibition of angiogenesis and MMP-2/9 activation was observed in vivo.
  • Antagonists exhibited superior potency compared to standard drugs with no host toxicity.

Conclusions:

  • Bradykinin antagonists represent a promising new class of anti-cancer drugs.
  • Their unique mechanism of action and favorable safety profile warrant further clinical development for cancer therapy.

More Related Videos

Analyzing Tumor and Tissue Distribution of Target Antigen Specific Therapeutic Antibody07:36

Analyzing Tumor and Tissue Distribution of Target Antigen Specific Therapeutic Antibody

Published on: May 16, 2020

Initial Evaluation of Antibody-conjugates Modified with Viral-derived Peptides for Increasing Cellular Accumulation and Improving Tumor Targeting11:58

Initial Evaluation of Antibody-conjugates Modified with Viral-derived Peptides for Increasing Cellular Accumulation and Improving Tumor Targeting

Published on: March 8, 2018

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
Antibody Actions01:26

Antibody Actions

Antibodies, or immunoglobulins, are critical players in the immune system's arsenal against invading pathogens. Produced by B cells and plasma cells, their primary role is to detect and bind to specific antigens, molecules found on the surface of pathogens like bacteria or viruses. Beyond antigen recognition, antibodies perform several vital functions that contribute to immune defense.
Neutralization
Antibodies can bind to pathogens, preventing them from infecting host cells. This process...
Antihypertensive Drugs: Angiotensin II Receptor Blockers01:30

Antihypertensive Drugs: Angiotensin II Receptor Blockers

In the renin-angiotensin-aldosterone system, a hormone called angiotensin II plays a crucial role. It binds to the AT1 receptors in vascular smooth muscles coupled with Gq proteins. The activation of these receptors activates an enzyme called phospholipase C, which releases two molecules: inositol trisphosphate and diacylglycerol. These molecules cause a chain reaction that leads to the phosphorylation of myosin light chains and promotes interaction between actin and myosin, leading to smooth...
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Receptor Downregulation in MVBs01:15

Receptor Downregulation in MVBs

Multivesicular bodies (MVBs) are mature endosomes that sort ubiquitinated proteins and then fuse with lysosomes to degrade the sorted proteins. Epidermal growth factor (EGF) and its receptor (EGFR) form a complex that can be internalized through endocytosis, sorted into an MVB, and later degraded.
The EGFR can initiate signaling pathways that  lead to cell proliferation, migration, and differentiation. Overexpression of EGFR  stimulates cells to proliferate. Excessive  EGFR activation may...